P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
367 Indexepoprostenol, 339
eptifibatide, 338
ergesterol, 331 –332
erythromycin, 318 –319
alfentanil concurrent administration,
146
esmolol,224t, 225t, 235–236
kinetics, 236
presentation, 235
side-effects, 236
uses, 235
ester hydrolysis, atracurium, 189
esterases, 18
muscle, 23
esters, 94
ethanol, metabolism, 18
ether link, 94
etomidate,112t, 114
effects,112t, 113t
GABAAreceptor, 101 –102
kinetics, 113 –114
presentation,112t
uses,112t
etoricoxib, 162
eutectic mixture of local anaesthetic
seeEMLA, topical
excretion of drugs, 19 –21
biliary, 21
drug interactions, 42
neonates, 23
renal, 20
exponential function, 52 , 53f, 54, 56f
exponential wash-out curve, semilogarithmic
transformation,59f
exponents, 54 –55
extraction ratio, 10 –11Fab,digoxin-specific, 232 –233
facilitated diffusion, 3
blood–brain barrier, 15
fade
AChreceptors, 175 –176
non-depolarizing muscle relaxants, 178
famotidine, 294
felypressin, epidural anaesthetics, 14
fentanyl, 145 –146
Bristol model of TIVA, 81 –82
context sensitive half-time, 77 –78
kinetics, 145 –146
lipid solubility, 6
presentation, 145
uses, 145
fetus, drug distribution, 15 –17
fibrin, 336
fibrinolysis, 335 –336fibrinolytic system, 335 –336
drugs affecting, 344 –346
fibrinolytics, 344 –345
Fick’s law, 5
first-pass metabolism,10f
avoidance, 11
bioavailability influence,9–10
flecainide, 240 –241
kinetics, 241
mechanism of action, 241
presentation, 240
side effects, 241
uses, 240
flucloxacillin, 314
fluconazole, 332 –333
flucytosine, amphoterocin B combination,
331 –332
fluid compartments, 298
distribution processes, 298 –300
neonates, 22
fluid replacement, 298 , 304t
flumazenil, 42 , 273–274
fluoxetine, 276
frusemide, 307 –308
aminoglycoside simultaneous use,
320
functional residual capacity (FRC), 116
functions, 50 –51
exponential, 52 –54
hyperbolic, 54
linear, 51
logarithmic, 54 –59
fusidanes, 325 , 328t
fusidic acid, 325 , 328tGABA, 86
agonist sites, 101 –102
GABAAreceptor,2–3, 25–26, 101–102, 270
benzodiazepine effects, 37 –38
GABAAreceptor complex, 101 –102
GABABreceptors, 270
gabapentin, 281
gallamine, 21 , 192
ganglion blockade, 268 –269
gastric motility, drugs affecting, 295
gastric secretion
drugs influencing, 293 –295
physiology, 292 –293
gastrin, gastric secretion physiology,
292 –293
gate theory of pain, 135 , 136f
gelatins, 300 –301
gene transcription regulation, 31
general anaesthesia, monoamine oxidase
inhibitor therapy, 277 –278